You're Invited!

Patient-2-Patient Education Project 2020

Presented By:
Michigan Medicine IBD Program
&
The Crohn’s and Colitis Student Initiative at the University of Michigan

This year’s event will be held virtually on October 3rd. For more information and to register please visit:

https://attendee.gotowebinar.com/register/5073405444295961104

It's That Time Again

Every year at this time we start talking to our IBD patients about how important it is to get their flu vaccine. Many of our IBD patients are on medications that weaken their immune systems and put them at greater risk for this seasonal infection.

As you may have heard, there is another factor that we are taking into consideration this year. The coronavirus is threatening to cause even greater damage during this upcoming flu season and one small step you can take to help protect yourself is by getting your flu vaccine. Though this will not protect you from the pandemic sweeping across the country in waves, it will make you less vulnerable than if your body is forced to fight against two potentially deadly respiratory infections.

If you are not planning on seeing either your IBD physician or general practitioner, there are many options in each community that can provide you with inexpensive or even free vaccines. Most CVS and Walgreen’s drugstores are providing these for their communities.

There is also an excellent resource that will help you find locations near you, VaccineFinder.org. You just choose which vaccine you’re looking for and your zip code to find locations near you that are offering the vaccines.
Currently Enrolling Clinical Trials

Ulcerative Colitis

M16-006—Risakinnub

*IV Induction / Subcutaneous injections for maintenance*

This is a phase 3 study to evaluate the safety and efficacy of Risakinnub in subjects with moderate to severe Ulcerative Colitis. If eligible, subjects could be in the study for up to 272 weeks.

ECO-RESET

*Oral capsule*

This is a phase 2b study for patients with active, mild to moderate Ulcerative Colitis to evaluate the safety and effectiveness of a new medication that will introduce healthy bacteria to the gut without suppressing the immune system.

Crohn’s Disease

ABT494—Upadacitinib

*Oral tablet*

This is a phase 3 study to evaluate the safety and efficacy of Upadacitinib in subjects with moderate to severe Crohn’s Disease. If eligible, subjects could be in the study for up to 244 weeks.

We are constantly on the search for new studies that provide viable options to our patients and partnering physicians.

Check with our Research Team at higginscresteam@umich.edu.

Observational Studies

**Biofire:** To determine if intestinal infections are associated with flares of irritable bowel syndrome with diarrhea

**Corrona Registry:** Provide information that may help with future treatment options for patients with IBD

**Databank:** Collect various samples from healthy volunteers and those with IBD

**FitBit Steroid Taper:** Track the outcomes of steroid tapers with the use of a FitBit wristband. The FitBit will monitor activity levels, sleep and heart rate in order to predict the outcomes of steroid tapers and predict future flares. Patients who are tapering off of prednisone and have Ulcerative Colitis or Crohn’s Disease are eligible to participate.

**Sparc:** Identify new tests to predict who will respond to what treatment

**Target:** 5 year study for adults and pediatrics to specifically address clinical questions that remain unanswered from registration trials

IBD CLINICAL RESEARCH TEAM

Kelli Porzondek  Zack Bearinger  Jay Bester  Andy Brosius  Jen Dixon  Angie Theil

Are you interested in learning more about something you read here? Contact our team at: higginscresteam@umich.edu